Of the 27 patients with TP53-mutated AML in our trial, 13 patients were treated in AFTER and achieved a CR/CRi rate of 46%, whereas CR/CRi rate in the remaining patients was only 21%, but this difference was not statistically significant (p = 0.23). This evidence concerns the gene TP53 and acute myeloid leukemia.